FDA Clears Cingulate to File NDA for CTx-1301 in the Treatment of ADHD
The company has announced plans to submit the NDA in the first half of 2025.
Source: psychiatrictimes.com
Cingulate Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Cingulate Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Cingulate Inc Today - Breaking & Trending Today
FDA Clears Cingulate to File for Marketing Approval of
Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application Advancing Discussions with Commercialization Partners...
Source: globenewswire.com
FDA Clears Cingulate to File for Marketing Approval of CTx-1301 in the Treatment of ADHD
Phase 3 Data Collected to Date Sufficient for Submission of New Drug Application CTx-1301 Could Benefit >60% of ADHD Patients Currently ...
Source: businessinsider.com
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board ...
KANSAS CITY, Kan., April 30, 2024 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform technology to build and
Source: eagletribune.com
Peter J. Werth, Successful Pharma Entrepreneur, Philanthropist, Cingulate Investor and Board Member, to be Featured with Chairman and CEO Shane J. Schaffer on Benzinga All Live Access
KANSAS CITY, Kan., April 30, 2024 -- Cingulate Inc. , a biopharmaceutical company utilizing its proprietary Precision Timed Release™ drug delivery platform technology to build and advance a...
Source: marketscreener.com